Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoarthritis of the Knee, Coagulopathy
Interventions
Pennsaid
Drug
Lead sponsor
Nathan Wei, MD, FACP, FACR:
Other
Eligibility
55 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Frederick, Maryland
Conditions
Secondary Post Tonsillectomy Hemorrhage, Primary Post Tonsillectomy Hemorrhage
Interventions
Ibuprofen
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Fort Sam Houston, Texas • Lackland Air Force Base, Texas • Tacoma, Washington
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Completed Phase 3 Interventional Results available

Naproxen Sodium Extended-Release Actual Use Study

NCT00751400
Conditions
Pain
Interventions
Naproxen Sodium ER (BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
24
States / cities
Anaheim, California • Oceanside, California • San Dimas, California + 20 more
Conditions
Cesarean Delivery, Postpartum Comfort, Postpartum Pain, Post-operative Pain, NSAIDs, Acetaminophen (D000082)
Interventions
Acetaminophen, NSAID (Ketorolac/Ibuprofen)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
16 Years and older · Female only
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Actual Use Trial of Naproxen Sodium

NCT01427803
Conditions
Pain
Interventions
Naproxen Sodium ER (BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
34
States / cities
Hoover, Alabama • McCalla, Alabama • Pinson, Alabama + 29 more
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Conditions
Acute Pancreatitis
Interventions
Ketorolac, Opioid
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Dysmenorrhea, Pain
Interventions
Naproxen
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Evanston, Illinois
Conditions
Distal Radius Fracture
Interventions
Ibuprofen, Acetaminophen
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Patient Narcotic Requirements After Outpatient Otolaryngology Procedures

NCT03404518
Conditions
Outpatient Surgery, Pain, Postoperative
Interventions
Norco, Ibuprofen
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 89 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Loma Linda, California
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions
KindVR Aqua Program
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
8 Years to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Pain, Postoperative
Interventions
CYP2D6-guided opioid therapy
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gainesville, Florida • Summerfield, Florida
Conditions
Healthy
Interventions
PA32540, PA32540 and celecoxib, aspirin and [NSAID]
Drug
Lead sponsor
POZEN
Industry
Eligibility
50 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Anaheim, California
Conditions
Rib Fractures
Interventions
Ropivacaine, Non steroidal anti-inflammatory drug and opioids
Drug
Lead sponsor
Zachary Warriner
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Cesarean Delivery, Cesarean Section, Pain, Postoperative, Opioid Consumption, Postoperative
Interventions
Suzetrigine, Placebo
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Hypertension, Renal Insufficiency, Chronic
Interventions
Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
542 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sleep and Inflammatory Resolution Pathway

NCT03377543
Conditions
Inflammatory Response, Inflammation, Sleep, Sleep Restriction
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
Interventions
pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID
Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
5 Days to 14 Days
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • San Jose, California + 9 more
Conditions
Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions
ZYNRELEF 200Mg-6Mg Extended-Release Solution
Drug
Lead sponsor
Dr. Yannis Raftopoulos
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Holyoke, Massachusetts
Not listed Phase 4 Interventional Accepts healthy volunteers

Pain Control After Lumbar Spine Fusion

NCT06484192
Conditions
Spine Fusion, NSAID (Non-Steroidal Anti-Inflammatory Drug), Postoperative Pain
Interventions
Naproxen 500 Mg, Ketorolac, OxyCODONE 5 mg Oral Tablet, Metaxalone 800 MG
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Fractures
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 16 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbia, Missouri